Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | YAP1 | P46937 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16096333 | 0.83 | CTSL (0.55) | KMT2AMAPK1NPC1GPR119CTSL | |
| SCHEMBL21062628 | 0.79 | GPR119 (0.56) | L3MBTL1GPR119CTSLYAP1 | |
| SCHEMBL22552460 | 0.79 | GPR119 (0.56) | L3MBTL1GPR119CTSLYAP1 | |
| SCHEMBL22552461 | 0.79 | GPR119 (0.56) | L3MBTL1GPR119CTSLYAP1 | |
| SCHEMBL2554913 | 0.79 | GPR119 (0.54) | KMT2AMAPK1GPR119CTSL | |
| SCHEMBL1439194 | 0.77 | MMP13 (0.54) | GPR119HPGD | |
| SCHEMBL2603249 | 0.76 | POLB (0.68) | POLBL3MBTL1KMT2ANPC1TDP1 | |
| SCHEMBL21096445 | 0.75 | CPN1 (0.45) | KMT2A | |
| SCHEMBL22031555 | 0.75 | L3MBTL1 (0.71) | POLBSIGMAR1L3MBTL1KMT2ANPC1 | |
| SCHEMBL16096742 | 0.74 | CTSL (0.52) | KMT2AMAPK1NPC1CTSLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385508-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7026316-B2 | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1385508-A4 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040106656-A1 | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. | 2004-06-03 | — | — | US | disclosed |
| EP-1385508-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002076450-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106656-A1 | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | POLB 2263/4885SIGMAR1 4713/4885L3MBTL1 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.